pan-species, multi-antigen platform for the detection and monitoring of SARS-CoV-2-specific antibody responses. A flexible

The SARS-CoV-2 pandemic and the vaccination effort that is ongoing has created an unmet need for accessible, affordable, flexible and precise platforms for monitoring the induction, specificity and maintenance of virus-specific immune responses. Herein we validate a multiplex (Luminex-based) assay capable of detecting SARS-CoV-2-specific antibodies irrespective of host species, antibody isotype, and specimen type (e.g. plasma, serum, saliva or blood spots). The well-established precision of Luminex-based assays provides the ability to follow changes in antibody levels over time to many antigens, including multiple permutations of the most common SARS-CoV-2 antigens. This platform can easily measure antibodies known to correlate with neutralization activity as well as multiple non-SARS-CoV-2 antigens such as vaccines (e.g. Tetanus toxoid) or those from frequently encountered agents (influenza), which serve as stable reference points for quantifying the changing SARS-specific responses. All of the antigens utilized in our study can be made in-house, many in E. coli using readily available plasmids. Commercially sourced antigens may also be incorporated and newly available antigen variants can be rapidly produced and integrated, making the platform adaptable to the evolving viral strains in this pandemic.

Shen, H., Forgacs, D., Chapla, D., Moremen, K. W., Wells, L., Hamer, S. A., ... Tarleton, R. L.

Shen, Huifeng||Forgacs, David||Chapla, Digantkumar||Moremen, Kelley W||Wells, Lance||Hamer, Sarah A||Tompkins, Stephen M||Ross, Ted M||Rouphael, Nadine||Edupuganti, Srilatha||Collins, Matthew H||Tarleton, Rick L

A flexible, pan-species, multi-antigen platform for the detection and monitoring of SARS-CoV-2-specific antibody responses. Institutional Repository Document